first large study of glp-1 receptor agonists during pregnancy Frontiers Discontinuing GLP-1s before or early
Description
From Endocrinology to Obesity Medicine: A Shift in Prescribing Authority The expansion of GLP-1 therapies into weight management has not only changed what these drugs are used for, but also who is prescribing them and under what clinical framework

Nauck MA, Meininger G, Sheng D, et al

Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes

The development of GLP-/GIP dual agonists provides a more complete scheme for the treatment of metabolic diseases, but the safety of more dual agonists or multiple agonists in clinical trials is also worthy of attention

Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials

Recent studies have also explored the ocular risks associated with GLP-1 therapies
